Recordati : Un peu plus prudent pour ce S2 2020
>Un fort ralentissement au T2 mais une marge bien contrôlée - Recordati publiait hier en séance ses résultats du T2 qui se sont révélés globalement en ligne avec les attentes. La topline montre un ralentissement à -8% à 331 M€ sur la période. Celle-ci est logiquement impactée par des effets de déstockage chez les grossistes et un ralentissement notable des visites médicales. Cette baisse est homogène entre ses revenus internationaux et issus de son marché local. Comme...Recordati-Industria Chimica e Farmaceutica is a pharmaceutical group based in Italy. Co.'s operations are divided into two operating segments: pharmaceuticals (and pharmaceutical chemicals) and orphan drugs. Co.'s products include ZANIPRESS®/ZANEXTRA®/LERCAPREL®/LERCARIL®, an antihypertensive drug; ZANIDIP®/CORIFEO®/LERCADIP® (lercanidipine), an antihypertensive drug discovered and developed in Co.'s research laboratories; UROREC® (silodosin), a new drug indicated for the treatment of benign prostatic hyperplasia; and LIVAZO®/ALIPZA® (pitavastatin), a statin for the treatment of dyslipidemia, among others.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.